Positive news about COVID vaccines will be weighed against concerns about new variants

The COVID-19 vaccine, developed by Pfizer and its German partner BioNTech SE, proved to be as effective as clinical trials in the first major study of a double-dose regimen involving 1.2 million people in Israel. it was done.

The data was peer-reviewed and published to leading companies Wednesday’s New England Journal of Medicine, They found that the vaccine reduced symptomatological cases of COVID by 94% in all age groups. According to the author, it also reduced serious illness by 92%.

“This study in a national mass vaccination environment suggests that the BNT162b2 mRNA vaccine is effective against a wide range of Covid-19-related results, consistent with the results of randomized trials,” the authors said. Are writing.

News comes as Pfizer

And BiotN Tech

They said so Test the third dose of their vaccine See if boosters are effective in treating new variants of the virus that have emerged in the United Kingdom, Brazil, and South Africa and are currently prevalent in the United States and elsewhere.

“There is no evidence that circulating mutants result in the loss of protection provided by the vaccine, but act decisively in case the strain becomes resistant to the protection provided by the vaccine. We are taking multiple steps to get ready. ” Albert Bourla, CEO of Pfizer. “This booster immunological study is important for understanding the safety of the third dose and immunity to circulating strains.”

US Food and Drug Administration Advisory Board of Johnson & Johnson

At a special meeting on Friday, we will give a single dose of the COVID-19 vaccine and vote on whether they believe the benefits of the vaccine outweigh the risks. FDA said on Wednesday The vaccine showed no unexpected safety concerns, We hope to receive an emergency permit and provide doctors with more ammunition to deal with the crisis.

A new variant of the virus called B.1.526 has been discovered in New York City. According to the New York Times And it carries mutations that may compromise the effectiveness of the vaccine. The newspaper cited two separate teams of researchers. California Institute of Technology Another person who detected a new variant at Columbia University. The former posted the survey online on Wednesday, but the Colombian team submitted the survey to the preprint server, but it has not yet been published.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said NBC Today shows that mutations are more likely to occur unless people are vaccinated.

“This is a race between inoculating people with viruses and vaccines,” Fauci said. “The longer you wait for someone to get vaccinated, the more likely the virus will have to get a mutant or mutation, so the sooner the vaccine gets into an individual’s arm, the better. The sooner, whatever the vaccine, if the FDA gets the vaccine, get it, if it’s available. “

For New York City’s new stock, Forch said such a variant would occur. “The secret is to prevent them from spreading when they occur,” he said.

Fauci also provided up-to-date information on a new US initiative to study so-called COVID “long-haul carriers.” Symptoms of these patients may worsen within a few months of recovery.A study published last week Journal of American Medical Association It was found that about 30% of COVID-19 patients reported symptoms that did not shake for up to 9 months after becoming ill.

“We don’t really understand the syndrome,” said Forch, president of President Joe Biden.

“It finds the mechanism by which we follow them, how long it is, how long it is, and what we call the etiology, why people have extreme fatigue. That’s why we’re developing a large cohort of people for muscle aches, thermoregulation, sleep disorders, and what they call brain fog, which is difficult to focus and focus on. That means that it is something we have to look at very carefully and we are. “

Approximately $ 1.5 billion was funded to fund the research.

The United States added 70,768 new COVID cases on Wednesday. According to the New York Times tracker And at least 3,210 people died. However, the number of cases is steadily declining, with an average of 68,123 days a day for the past week, a 35% decrease from the average two weeks ago.

There were 54,118 COVID patients in a US hospital on Wednesday.According to the COVID tracking project It is the lowest level since November 5th, down from 55,058 a day ago. Hospitalization has decreased by 59% from its peak in January.

In terms of vaccines Centers for Disease Control and Prevention Vaccine Tracker As of 6 am on Wednesday, 88.7 million doses were distributed to the state, 66.5 million doses were administered, indicating that 45 million people received at least one dose.

In other news:

• GlaxoSmithKline

United Kingdom: GSK

He said the experimental monoclonal antibody therapy did not meet the primary endpoints of the mid-term trial evaluating its use in hospitalized COVID-19 patients of all ages. Reported by Jaimy Lee of MarketWatch.. As part of the study’s design, the treatment Ochilimab was given in addition to standard treatments, including treatments such as Gilead Sciences.

Antiviral Beckleley. GSK refocused the study on patients over the age of 70 after data from the study showed that antibody treatment was likely to improve outcomes in older patients, with 350 people meeting this demographic. He said he had plans to register. GSK said it plans to publish details of the first Phase 2 trial in a preprint.

• President Biden and Vice President Kamala Harris mark the 50 millionth vaccine shot in the United States at a White House event later Thursday.

• Ultimate Inc.

Trading fell 4.8% on Thursday after the company announced that it had begun enrolling participants in Phase 1 clinical trials of COVID-19 vaccine candidates. Altimmune is developing a single-dose nasal spray vaccine. The study is expected to enroll up to 180 healthy adults between the ages of 18 and 55. These adults receive one of three doses of the experimental vaccine. The company said it plans to share the first clinical data for the trial in the second quarter of this year.

• Regeneron Pharmaceuticals Inc.

The Independent Committee said the company’s antibody cocktail showed “clear” efficacy and recommended that patients with COVID-19 not receive placebo in a phase 3 clinical trial. The Commission said the urgently licensed treatment REGEN-COV in November reduced hospitalization and mortality at two dose levels and will continue to enroll unhospitalized COVID-19 patients receiving both doses of treatment. It was. The company said it plans to share detailed clinical data from next month’s trials as part of its efforts to ensure full approval from the Food and Drug Administration for antibody cocktails.

• Finland will enter a three-week blockade starting March 8 to contain the increasing number of COVID cases. Reuters reported. The Nordic countries are widely praised for their successful control of last spring’s pandemic, which was prevalent elsewhere in Europe. Prime Minister Sanna Marin said she was ready to declare a state of emergency next week after discussing this with the president. Among other things, emergencies will allow restaurants to be closed, and healthcare professionals will work longer and demand that their holidays be cancelled. In Finland, 55,687 COVIDs have been confirmed. According to data compiled by Johns Hopkins University And 737 dead.

Latest tabulation

Global aggregates of confirmed cases of coronavirus causing COVID-19 exceeded 112.6 million Thursday, according to Johns Hopkins data, with deaths exceeding 2.49 million.

At least 63.5 million people have recovered from COVID.

The United States recorded the highest number of cases in the world at 28.3 million and the highest death toll at 505,899 after surpassing the level of 500,000 at the end of Monday. There was bad news from California. California has the highest number of deaths in any state, with more than 50,000 deaths.

Brazil has the second highest number of deaths at 249,957 and the third highest number of cases at 10.3 million.

India is the second largest in the world with 11 million cases and is currently the fourth largest with 156,705 deaths.

The death toll in Mexico is 182,815, the third highest, and the number of cases is 2.1 million, the 13th highest.

The UK has 4.2 million cases and 121,979 deaths, the highest in Europe and the fifth highest in the world.

China, Where the virus was first discovered at the end of last year, According to official figures, there were 100,832 confirmed cases and 4,834 deaths.

What is the economy saying?

US makers in January recorded the largest increase in orders in six months, demonstrating an economy that is gaining momentum again after disappointment at the end of 2020. Reported by Jeffry Bartash of MarketWatch.

Orders for durable consumer goods (products that last at least three years) increased by 3.4% in January, according to the government. Economists surveyed by Dow Jones and The Wall Street Journal predicted a 1% increase.

read: Inflation concerns are back. Do you need to worry?

Apart from this, new applications for unemployment benefits in the United States plummeted to the lowest level in three months in late February, but the still high number of layoffs is the record-breaking coronavirus storm last winter. It shows that the economy is slowly recovering from the attack.

The first unemployment claims traditionally filed through the state decreased from 111,000 to 730,000 in the week ending February 20th. The government said on thursday..

The sharp decline was much greater than expected, but recently billing data has become very volatile and unreliable due to snuff processing, bad weather and other issues. Economists surveyed by Dow Jones and The Wall Street Journal predicted that the new bill would be seasonally adjusted to 845,000.

Another 451,402 benefit applications were submitted through the Temporary Federal Relief Program.

Summing up the new state and federal claims, the government received 1.16 million unemployment allowance applications last week, based on real or unadjusted figures.

Finally, according to the latest data released Thursday by the US Department of Commerce, the US economy expanded at an annual rate of 4.1% instead of 4% in the fourth quarter. As reported by Greg Robb of MarketWatch.

Economists surveyed by The Wall Street Journal predicted that gross domestic product in the fourth quarter would rise to an annual growth rate of 4.2%.

Federal Reserve Board Chair Jerome Powell said this week that strong growth later this year is expected to be what he sees as the most likely for the economy. He said the 2021 6% growth rate cannot be ruled out. Today’s slight increase in GDP in the fourth quarter did not change the government’s estimate that the economy would shrink at a rate of 3.5% in 2020 as the pandemic led to an unprecedented outage.

Economists surveyed by the Journal are expected to grow 2.8% in the first three months of the year and 6% in the second quarter.

Dow Jones Industrial Average

And S & P 500

Moved down.

Positive news about COVID vaccines will be weighed against concerns about new variants

Source link Positive news about COVID vaccines will be weighed against concerns about new variants

Back to top button